Product Images Aripiprazole

ARIPiprazole is a tablet with a dose of 10mg, and comes in a quantity of 30 tablets. It is RX only and should be kept out of reach of children. The source NDC is 13668-0218-30 and it was manufactured by Torrent Pharma Inc. in Basking Ridge, NJ 07620. The medication should be stored at 20-25°C (88-77°F) with permitted excursions to 15-30°C (59-86°F) [See USP]. The directions for use can be found in the package insert. It was repackaged by RemedyRepack Inc. in Indiana, PA 15701, and their contact number is 724.465.8762.*

This is a figure (Figure 1) showing the effect of various drugs on the pharmacokinetics of aripiprazole. The drugs shown include inhibitors and inducers of CYP3M, CYP2D6, and CYPIM, as well as a gastric acid blocker and other drugs. The graph shows the change relative to the reference (without any interacting drug) for each drug.*

Figure 3 shows the effect of Aripiprazole on the pharmacokinetics of various drugs. The table includes different drugs such as Demopmetorphan, Rowarfarin, Lamotrigine, Valproate, Litum, Lorazepam, Venlafaine and Veniatasine, O-desmetnyheniataing, and Escitalopram. The values represent the fold change and 90% C1 for each drug. The x-axis indicates the percentage of change relative to the reference without an interacting drug.*

The figure shows the effect of intrinsic factors on Aripiprazole pharmacokinetics in special populations. The chart displays the fold change and 90% confidence interval of PK Aripiprazole in different subgroups of individuals based on their CYP206 status, gender, age, hepatic impairment, and renal impairment. Not available.*

The figure displays the impact of various intrinsic factors on Dehydro-Aripiprazole pharmacokinetics, represented as PK Dehydro-Aripiprazole Fokd Change along with a 90% confidence interval. The intrinsic factors evaluated in the study were CYP206 metabolizer status, gender, age, hepatic impairment, and renal impairment. The figure shows the relative change in AUC and Cmax concerning the reference values.*

This is a Kaplan-Meier estimation chart comparing the cumulative proportion of patients with relapse between a group taking Aripiprazole and a group taking a placebo in a bipolar study (number 7). The chart shows the number of subjects at risk over time (in days from randomization) for each group, but no further information is given.*

This is a figure (Figure 8) which shows Kaplan-Meier estimation of the cumulative proportion of patients with a relapse to any mood event in a bipolar study (Bipolar Study 8). The graph shows the proportion of relapse against the number of subjects at risk over time in days from randomization. There are no other details available from the text.*

The text describes a figure (Figure 9) that shows the change in YGTSS TTS (Tic Rating Scale) over time, by week, for a study involving Tourette's Disorder. The figure presents Least Square Means of Change from Baseline. The text also gives information on the number of patients (5 Tots) and presents the results (Lirst-Scymwess Mesan Changs in YGTS) in a table or graph format, divided by weeks of treatment.*